<div id="readability-page-1"><div><div><table><tbody><tr><td><span>Reporter Name</span></td><td><span>Friedman Paul A</span></td></tr><tr><td><span>Relationship</span></td><td><span>Director, 10% Owner</span></td></tr><tr><td><span>Type</span></td><td><span>Sell</span></td></tr><tr><td><span>Amount</span></td><td><span>$13,694,157</span></td></tr><tr><td><span>SEC Filing</span></td><td>Form 4</td></tr></tbody></table></div><p><span>Paul A Friedman, a 10% owner and director of MADRIGAL PHARMACEUTICALS, sold 24,800 shares of common stock on December 10, 2025, for a total of $13,694,157. The sales were executed at weighted average prices ranging from $547.7462 to $555.39, under a Rule 10b5-1 trading plan adopted on September 10, 2025. Following these transactions, Friedman directly owns 187,164 shares and indirectly owns 655,540 shares through SQN LLC. The sales prices reported are weighted averages, with transactions occurring at various prices within specified ranges.</span></p><p><span>SEC Filing: </span>MADRIGAL PHARMACEUTICALS, INC. [ MDGL ] - Form 4 - Dec. 12, 2025</p></div></div>

MDGL

<p>Paul A. Friedman, a director and 10% owner of Madrigal Pharmaceuticals, sold 24,800 shares for $13,694,157 on December 10, 2025. The sales were part of a Rule 10b5-1 trading plan adopted in September 2025. Post-sale, Friedman holds 187,164 shares directly and 655,540 shares indirectly through SQN LLC.</p>

MADRIGAL PHARMACEUTICALS Director Sells Shares Worth Over $13 Million